Gilead drug extends lives in study of leukemia patients
This article was originally published in Scrip
Executive Summary
Gilead Sciences said its experimental drug idelalisib combined with the cancer drug Rituxan significantly extended lives of leukemia patients and slowed the disease from worsening in a late-stage study.